Eurofins Scientific: A New Buyback Program Covering 4.5% of Capital
Eurofins Scientific announces the launch of its seventh buyback program for its own shares, with a maximum amount representing 4.5% of its share capital. This program, starting April 24, 2026, follows the sixth program which took place between April 25, 2025, and April 23, 2026.
The new buyback program will extend until April 23, 2027, at the latest. The first tranche, managed by an independent financial services provider, will begin on April 24, 2026, and end on June 23, 2026, with a maximum volume of 7,920,000 shares, representing 4.5% of the current share capital. The provider is authorized to make purchases on regulated markets, limited to 25% of the average daily transaction volume of the last twenty trading days, as well as block purchases on the free market. The total volume of shares repurchased on any trading day will not exceed 50% of the average daily volume of the last twenty trading days.
Use of Repurchased Shares
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The shares acquired under this program will be used to cover the company's long-term incentive plans. They may also be cancelled, used to partially finance acquisitions, or used for other purposes approved by the board of directors and authorized by the general meeting held on April 23, 2026. Eurofins may suspend this program at any time depending on market conditions and changes in its investment strategy.
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
